Business
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico\n\n\n\n MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT\n \n ®\n \n IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries (United Medical Ltd. and Grupo Biotoscana de Especialidad S.A. de C.V., respectively).\n \n\n In May 2022, Knight and Helsinn Healthcare SA (\"Helsinn\") had entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO\n \n ®\n \n (netupitant/palonosetron - fosnetupitant /palonosetron) in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI\n \n ®\n \n oral/IV (palonosetron) in Canada. In January 2025, Knight and Helsinn announced that they expanded their existing relationship and entered into an exclusive license, distribution and supply agreement for ONICIT\n \n ®\n \n IV (palonosetron) in Mexico, Brazil, and other LATAM countries. ONICIT\n \n ®\n \n is marketed under the brand name ALOXI\n \n ®\n \n in Canada.\n \n\n ONICIT\n \n ®\n \n solution for injection is approved and marketed in Brazil and Mexico for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of moderately and highly emetogenic chemotherapy for cancer, and for the prevention of delayed nausea and vomiting associated with the initial and repeated cycles of moderately emetogenic chemotherapy for cancer in adults. In addition, ONICIT\n \n ®\n \n is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults, for up to 24 hours after surgery. In Brazil, ONICIT\n \n ®\n \n is also indicated for pediatric patients, from 1 month to 17 years of age, for the prevention of acute nausea and vomiting associated with the initial and repeated cycles of emetogenic chemotherapy for cancer, including highly emetogenic chemotherapy.\n \n\n “We are proud to continue providing patients and health care professionals with advanced treatments like ONICIT\n \n ®\n \n to help mitigate the debilitating effects of chemotherapy induced nausea and vomiting,” said Samira Sakhia, President and CEO of Knight. “ONICIT\n ...